MEDICINOVA INC
For the period ended Dec 31, 2023. Filed Feb 15, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 15, 2024
MNOV$1.40-4.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
| Years ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Revenues | $1,000,000 | $— |
| Operating expenses: | ||
| Research, development and patents | 5,657,895 | 9,143,792 |
| General and administrative | 5,242,370 | 5,484,857 |
| Total operating expenses | 10,900,265 | 14,628,649 |
| Operating loss | (9,900,265) | (14,628,649) |
| Interest income | 1,834,665 | 809,673 |
| Other expense, net | (502,869) | (247,285) |
| Loss before income taxes | (8,568,469) | (14,066,261) |
| Income tax expense | (3,047) | (2,822) |
| Net loss | $(8,571,516) | $(14,069,083) |
| Basic and diluted net loss per common share | $(0.17) | $(0.29) |
| Shares used to compute basic and diluted net loss per common share | 49,046,246 | 49,045,342 |
| Net loss | $(8,571,516) | $(14,069,083) |
| Other comprehensive loss, net of tax: | ||
| Foreign currency translation adjustments | (2,805) | (16,408) |
| Comprehensive loss | $(8,574,321) | $(14,085,491) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.